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OBJECTIVES: To estimate the cost-effectiveness of subcutaneously self-adminis-
tered icatibant for the symptomatic treatment of acute attacks of HAE in adults
with C1-INH deficiency.versus current clinical practice in Australia i.e., best sup-
portive care, with delayed use of intravenous C1-INH concentrate if required ad-
ministered in the hospital emergency setting.METHODS:An economic model with
Markov processes was developed to estimate the costs and benefits of self-admin-
istered icatibant compared to current clinical practice in Australia. The model
consisted of four health states (free of HAE attack, cutaneous HAE attack, abdom-
inal HAE attack, laryngeal HAE attack) with patients starting in the attack-free
health state and transitioning to one of the four health states at weekly cycles over
52 weeks. Variables in the model (probability of attack, probability an attack is
treated, duration of attack) were based on evidence from relevant clinical trials and
the wider literature. Utility values were derived from a survey of 201 members of
the Australian general public using a vignette/health state scenario based ap-
proach and standard gamble methodology. Costs were estimated from the per-
spective of the Australian public health care system. RESULTS: Incremental cost
per QALY of self-administered icatibant compared with current clinical practice in
Australia estimated by the model was $71,026. Incremental costs consisted of an
additional $8,864 in icatibant costs relative to C1-INH concentrate costs and a sav-
ing of $105 in the costs of attendances to accident and emergency department. The
majority of the QALY gains were due to the better quality of life whilst in the
attack-free health state, attributed to the “process utility” afforded by having ac-
cess to self-administration and living in the knowledge that when an attack occurs
it can be quickly and easily managed. CONCLUSIONS: This represents a reasonable
level of cost-effectiveness of icatibant in the context of a small patient population
and orphan indication.
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OBJECTIVES: To compare cost-effectiveness of controlled release ropinirole (ROP
CR) with levodopa (LD) and piribedil (PIR) in treatment of Parkinson’s disease in
Poland. METHODS: Lifetime Markov model from Polish public payer perspective
was developed. Two schemes: drug monotherapy (ROP CR vs LD and PIR) and
therapy added to levodopa (ROP CR vs LD) were considered. Effectiveness data were
taken from the systematic review of randomized clinical trials. Utility was modeled
based on the UPDRS values and dyskinesia occurrence. In the model Polish costs of
drugs, qualification, monitoring, hospitalization and dyskinesia treatment were
included. sensitivity analysis were performed for key model’s parameters.
RESULTS: Estimated lifetime QALYs per patient for comparison of monotherapies
were: 8.12 for ropinirole CR, 7.95 for levodopa and 7.89 for piribedil. Differences in
QALYs were statistically significant in favor of ropinirole CR for both comparators.
Average costs per patient were 76,710 PLN for ropinirole CR, 61,180 PLN for
levodopa and 62,860 PLN for piribedil. The ICERs for ropinirole CR were: 94,200 PLN
in comparison to levodopa and 59,780 PLN in comparison to piribedil. Estimated
lifetime QALYs per patient for comparison of ropinirol CR as add-on to levodopa
with levodopa monotherapy in higher doses were: 7.70 for ropinirole CR and 7.16
for levodopa. Differences in QALYs were statistically significant in favor of ropini-
role CR. Average costs per patient were 64,110 PLN for ropinirole CR and 18,420 PLN
for levodopa. The ICERs for comparison of ropinirol CR with levodopa was 84,920
PLN. CONCLUSIONS: Ropinirole is cost-effective in comparison to piribedil and
levodopa in monotherapy, and as add-on to levodopa in comparison to levodopa
monotherapy in higher doses (threshold of three GDP: 102,045 PLN).
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OBJECTIVES:To assess the costs of oral treatment with fingolimod (Gilenya®) com-
pared to intravenous infusion of natalizumab (Tysabri®) in patients with relapse
remitting multiple sclerosis (RRMS) in the The Netherlands. METHODS: A cost-
minimization analysis (CMA) was used to compare the costs of both treatments. In
this analysis drug acquisition costs, drug administration costs, and other costs
related to drug treatment were distinguished. Costs were discounted at 4%, and
incremental model results were presented over a 1, 2, and 10 year time horizon.
The robustness of the model results was determined by means of a number of
deterministic univariate sensitivity analyses and a probabilistic sensitivity analy-
sis. Additionally, a break-even analysis was carried out to determine at what IV
infusion costs a cost neutral outcome would be obtained. RESULTS: When fingoli-
mod was compared to natalizumab, the model predicted discounted incremental
costs of -€1,699 (95%CI: -€2,216;-€946), -€4,094 (95%CI: -€5,017;-€2,625), and -€20,218
(95%CI: -€24,192;-€13,977) over a 1, 2, and 10-year time horizon respectively. Results
of the sensitivity analyses showed that these predictions were most sensitive to
changes in the costs for IV administration of natalizumab. Changing these costs
within a range of €217 and €297 per IV infusion, resulted in cost savings varying
from €15,831 to €24,606 after 10 years. The additional break-even analysis showed
that IV infusion costs needed to be as low as €127 and €73 in order to obtain a cost
neutral result after 1 and 10 years respectively. CONCLUSIONS: The present anal-
ysis showed that treatment with fingolimod resulted in considerable cost savings
compared to natalizumab: €20,218 per RRMS patient in the The Netherlands after
10 years of treatment. The robustness of this estimate was confirmed within the
sensitivity analyses. The conclusions were in line with cost-utility analysis that has
been performed as well, showing cost savings of fingolimod compared to natali-
zumab.
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in
patients with uncontrolled partial-onset seizures in the Slovak Republic.
METHODS: The model simulated the treatment pathway of a hypothetical cohort
of 1000 patients over two years from the third party payer perspective in the Slovak
Republic using 2011 pricing. A decision tree was split into four phases of six months
each during which patients can become seizure free, experience a seizure reduc-
tion (responder defined as 50% reduction in seizures), or withdraw due to non-
response. The standard therapy arm included five adjunctive therapies: carbam-
azepine, lamotrigine, levetiracetam, topiramate and valproate. The likelihood of
being in a particular health state has been estimated from clinical trials data. The
cost of outpatient visits, inpatient and emergency department visits were included.
Costs and utility values attached to various health states were taken from the
published literature. RESULTS: Lacosamide adjunctive therapy was associated
with 6730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs),
compared with the standard therapy within the 2-year timeframe. Treatment with
lacosamide was associated with a cost of €103 per seizure avoided, and €18,402 per
QALY gained versus standard therapy over 2 years and falls within acceptable
thresholds of cost-effectiveness in Slovakia. Results calculated for 6-, 12- and 18-
month follow-up showed respective incremental cost-utility ratios of €20,904,
€19,443 and €19,133 and cost per seizure avoided of €276, €127 and €111. Using a
willingness-to-pay threshold of €26,500 per QALY, 83% of the simulations fell below
this value after 2 years of treatment. CONCLUSIONS: Lacosamide was shown to be
a cost-effective adjunctive treatment in patients with uncontrolled partial-onset
epilepsy in the Slovak Republic.
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OBJECTIVES: To assess the cost-utility of oral fingolimod (Gilenya) versus IV natali-
zumab (Tysabri) in active relapsing remitting multiple sclerosis (RRMS) from Bel-
gian healthcare (RIZIV/INAMI  patient), governmental and societal perspectives.
METHODS: A 40-year Markov model was developed containing 20 health states
describing disability severity based upon the Expanded Disability Status Scale
(EDSS): 10 RRMS EDSS states (0-9), 10 secondary progressive MS (SPMS) EDSS states
(0-9) and a death state. Per annual cycle, RRMS patients can remain stable, progress
to a higher RRMS EDSS state or convert to SPMS at a higher EDSS state. Patients
have a fixed annual probability of relapse and death (national age-adjusted mor-
tality). RRMS patients with EDSS score6.5 are eligible for disease modifying ther-
apies (DMTs). Patients with SPMS or EDSS score  6.5 receive best supportive care.
Transition probabilities were based on the natural history of RRMS and the relative
risk of confirmed disability progression and relapse per DMT. Efficacy of natali-
zumab (AFFIRM) and fingolimod (FREEDOMS) was based upon indirect comparison
with adjustment for differences in baseline disease characteristics and demo-
graphics. Belgian costs and utilities obtained from literature were assigned to each
EDSS level and to relapse. DMT monitoring and administration costs were based
upon expert opinion. Costs (3%) and outcomes (1.5%) were discounted. Probabilistic
sensitivity analyses covered variability in efficacy, costs and utilities. RESULTS:
Base-case analyses revealed cost-effectiveness of fingolimod from the health care
perspective and dominance from governmental and societal perspective. The
probability of fingolimod being cost-effective (35,000€/QALY) varied between 64%
and 70%. Results were sensitive to the hazard ratio of disability progression due to
wide and overlapping confidence intervals (indirect treatment comparison). Ex-
cluding uncertainty in this parameter resulted in probabilities of cost-effectiveness
between 81% and 100%.CONCLUSIONS: Treatment of active RRMS with fingolimod
was cost-effective from all payers’ perspectives versus treatment with natali-
zumab.
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OBJECTIVES: Multiple sclerosis (MS) is a neurodegenerative disease associated
with significant impairments in health related quality of life. This analysis was to
identify patient factors associated with utility in RMS patients and to derive dis-
utility values according to relevant disease stages. METHODS: TEMSO (N1088)
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